

Torsten Pietsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6822976/publications.pdf>

Version: 2024-02-01

74
papers

4,669
citations

218677

26
h-index

118850

62
g-index

75
all docs

75
docs citations

75
times ranked

5999
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
2	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. <i>PLoS ONE</i> , 2008, 3, e3088.	2.5	606
3	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478
4	cIMPACTâ€“NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€“utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
5	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3187-3193.	1.6	270
6	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanineâ€“DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	1.6	151
7	Outcome of patients with intracranial non-germinomatous germ cell tumorsâ€“lessons from the SIOP-CNS-GCT-96 trial. <i>Neuro-Oncology</i> , 2017, 19, 1661-1672.	1.2	150
8	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. <i>Journal of Clinical Oncology</i> , 2016, 34, 4151-4160.	1.6	121
9	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014, 135, 1822-1831.	5.1	117
10	H3F3A K27M Mutation in Pediatric CNS Tumors. <i>American Journal of Clinical Pathology</i> , 2013, 139, 345-349.	0.7	116
11	Supratentorial ependymomas of childhood carry C11orf95â€“RELA fusions leading to pathological activation of the NF- κ B signaling pathway. <i>Acta Neuropathologica</i> , 2014, 127, 609-611.	7.7	103
12	Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 301-306.	2.5	98
13	Expression of the Neurotrophin Receptor p75 ^{NTR} in Medulloblastomas Is Correlated with Distinct Histological and Clinical Features: Evidence for a Medulloblastoma Subtype Derived from the External Granule Cell Layer. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 229-240.	1.7	83
14	Childhood supratentorial ependymomas with <i>YAP1</i> â€“ <i>MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75
15	Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. <i>Neuro-Oncology</i> , 2016, 18, 919-927.	1.2	68
16	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	1.2	67
17	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. <i>Brain Pathology</i> , 2019, 29, 325-335.	4.1	55
18	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. <i>Neurology</i> , 2017, 88, 1422-1430.	1.1	54

#	ARTICLE	IF	CITATIONS
19	Vascular endothelial growth factor (VEGF) in astrocytic gliomas—a prognostic factor?. <i>Journal of Neuro-Oncology</i> , 1999, 45, 117-125.	2.9	53
20	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 791-797.	1.7	50
21	Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. <i>Journal of Neuro-Oncology</i> , 1999, 44, 23-33.	2.9	44
22	Supratentorial ependymoma in childhood: more than just RELA or YAP. <i>Acta Neuropathologica</i> , 2021, 141, 455-466.	7.7	37
23	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.	7.7	36
24	Systematic comparison of MRI findings in pediatric ependyoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. <i>Neuro-Oncology</i> , 2015, 17, 1157-1165.	1.2	33
25	YAP1/TAZ drives ependymoma-like tumour formation in mice. <i>Nature Communications</i> , 2020, 11, 2380.	12.8	32
26	Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?. <i>Brain Pathology</i> , 2021, 31, 20-32.	4.1	32
27	High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 110-120.	1.7	31
28	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica</i> , 2020, 140, 405-407.	7.7	30
29	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. <i>Clinical Neuroradiology</i> , 2019, 29, 595-604.	1.9	26
30	Pediatric ependymoma: an overview of a complex disease. <i>Child's Nervous System</i> , 2021, 37, 2451-2463.	1.1	26
31	Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. <i>Child's Nervous System</i> , 2021, 37, 809-818.	1.1	22
32	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	1.2	22
33	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. <i>American Journal of Neuroradiology</i> , 2017, 38, 1892-1898.	2.4	21
34	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features—a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica Communications</i> , 2019, 7, 181.	5.2	21
35	Absence of <i>TERT</i> promoter mutations in primary melanocytic tumours of the central nervous system. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 794-797.	3.2	19
36	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients—Report from the German SIOP-ILGG 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 3471-3489.	5.1	19

#	ARTICLE	IF	CITATIONS
37	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. <i>Journal of Neuro-Oncology</i> , 2019, 142, 435-444.	2.9	14
38	Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. <i>Child's Nervous System</i> , 2020, 36, 2693-2700.	1.1	14
39	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. <i>Advances in Radiation Oncology</i> , 2020, 5, 1158-1169.	1.2	13
40	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. <i>Neuro-Oncology Practice</i> , 2017, 4, 29-39.	1.6	12
41	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. <i>Cancers</i> , 2022, 14, 126.	3.7	12
42	<i>MGMT</i> promoter methylation analysis for allocating combined <i>CCNU</i> / <i>TMZ</i> chemotherapy: Lessons learned from the <i>CeTeG</i> / <i>NOA</i> trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	5.1	11
43	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11
44	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4267.	4.1	10
45	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	2.4	9
46	Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. <i>Familial Cancer</i> , 2021, 20, 273-277.	1.9	9
47	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. <i>Neuro-Oncology</i> , 2021, 23, 1148-1162.	1.2	9
48	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. <i>Cancers</i> , 2022, 14, 471.	3.7	9
49	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <i>WHO</i> grade <i>II</i> – Report from the German/Swiss <i>SIOP</i> <i>LGG</i> 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 2159-2175.	5.1	8
50	GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY – EARLY RESULTS OF THE SIOP CNS GCT II STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii343-iii344.	1.2	8
51	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3K27M Mutant Diffuse Midline Glioma. <i>Clinical Neuroradiology</i> , 2022, 32, 249-258.	1.9	8
52	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	7.7	7
53	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of <i>MGMT</i> Promoter Methylation Status. <i>Pharmaceuticals</i> , 2021, 14, 195.	3.8	7
54	Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 419-430.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. <i>Oncotarget</i> , 0, 7, 41898-41912.	1.8	7
56	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. <i>Journal of Neuro-Oncology</i> , 2021, 155, 193-202.	2.9	6
57	Mutated SON putatively causes a cancer syndrome comprising high-risk medulloblastoma combined with café-au-lait spots. <i>Familial Cancer</i> , 2019, 18, 353-358.	1.9	4
58	Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region. <i>Neuro-Oncology</i> , 2019, 21, 137-138.	1.2	3
59	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82.	1.2	2
60	Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 425-433.	1.3	2
61	OT-10 * IMPLEMENTATION OF NEXT GENERATION COPY NUMBER AND MUTATIONAL ANALYSIS IN ROUTINE NEUROPATHOLOGY: MOLECULAR INVERSION PROFILING IS A HELPFUL TOOL IN DIFFERENTIAL DIAGNOSTICS AND PROGNOSTICATION OF PEDIATRIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2015, 17, iii30-iii31.	1.2	1
62	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. <i>Neuro-Oncology</i> , 2018, 20, i144-i145.	1.2	1
63	EPEN-07. EPENDYMOMAS IN INFANCY: UNDERLYING GENETIC ALTERATIONS, HISTOLOGICAL FEATURES AND CLINICAL OUTCOME. <i>Neuro-Oncology</i> , 2019, 21, ii78-ii78.	1.2	1
64	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 475-484.	1.6	1
65	MB-28 * GENOME-WIDE COPY NUMBER ANALYSIS, NEUROPATHOLOGICAL CLASSIFICATION AND ANALYSIS OF HEDGEHOG ACTIVATION: HISTOLOGY REFLECTS GENETICS AND BIOLOGY IN MEDULLOBLASTOMAS OF YOUNG CHILDREN. <i>Neuro-Oncology</i> , 2015, 17, iii26-iii26.	1.2	0
66	ATRT-15. SPINAL CORD ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) IN CHILDREN: RESULTS OF A EUROPEAN RETROSPECTIVE ANALYSIS UNDER THE AUSPICES OF THE EU-RHAB STUDY GROUP. <i>Neuro-Oncology</i> , 2018, 20, i30-i30.	1.2	0
67	TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICSâ€”THE PROSPECTIVE MNP2.0 STUDY. <i>Neuro-Oncology</i> , 2018, 20, i181-i181.	1.2	0
68	MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES. <i>Neuro-Oncology</i> , 2018, 20, i127-i127.	1.2	0
69	EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS â€” A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT. <i>Neuro-Oncology</i> , 2020, 22, iii313-iii313.	1.2	0
70	HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN. <i>Neuro-Oncology</i> , 2020, 22, iii349-iii350.	1.2	0
71	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORSâ€”THE MNP 2.0 STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii426-iii426.	1.2	0
72	EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication. <i>Neuro-Oncology</i> , 2022, 24, i44-i44.	1.2	0

#	ARTICLE	IF	CITATIONS
73	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). <i>Neuro-Oncology</i> , 2022, 24, i72-i73.	1.2	0
74	GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy – final of the SIOP CNS GCT II study. <i>Neuro-Oncology</i> , 2022, 24, i56-i56.	1.2	0